FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2935132327> ?p ?o ?g. }

• W2935132327 endingPage "1604" @default.
• W2935132327 startingPage "1600" @default.
• W2935132327 abstract "Treatment of neuroendocrine tumors with ¹⁷⁷Lu-octreotate results in prolonged survival and improved quality of life for the patient. However, the treatment is today limited by side effects on kidney and bone marrow, and complete tumor remission is rarely seen. A possible way to minimize dose-limiting toxicity and to optimize this treatment method is to use radioprotectors in conjunction with radiotherapy. A recombinant form of α₁-microglobulin (rA1M) was recently shown to preserve kidney structure and function after ¹⁷⁷Lu-octreotate injection in mice and was suggested as a radioprotector in peptide receptor radionuclide therapy. The aims of this work were to investigate the influence of rA1M on the in vivo biokinetics of ¹⁷⁷Lu-octreotate, with a focus on tumor tissue, and to study the impact of rA1M on the therapeutic response in tumor tissue subjected to ¹⁷⁷Lu-octreotate treatment. <b>Methods:</b> The biodistribution of ¹⁷⁷Lu-octreotate was examined in BALB/c nude mice with GOT2 tumors 1–168 h after injection with either ¹⁷⁷Lu-octreotate or coadministration of ¹⁷⁷Lu-octreotate and rA1M. The effects of rA1M on the tumor response after ¹⁷⁷Lu-octreotate treatment were studied in BALB/c nude mice with GOT1 tumors. Three groups of mice were administered rA1M, ¹⁷⁷Lu-octreotate, or both. Another group served as untreated controls. Tumor volume was measured to follow the treatment effects. <b>Results:</b> No statistically significant difference in biodistribution of ¹⁷⁷Lu was observed between the groups receiving ¹⁷⁷Lu-octreotate or coinjection of ¹⁷⁷Lu-octreotate and rA1M. The therapy study showed a decrease in mean tumor volume during the first 2 wk for both the ¹⁷⁷Lu-octreotate group and the coadministration group, followed by tumor regrowth. No statistically significant difference between the groups was found. <b>Conclusion:</b> rA1M did not negatively impact absorbed dose to tumor or therapeutic response in combination with ¹⁷⁷Lu-octreotate and may be a promising kidney protector during ¹⁷⁷Lu-octreotate treatment of patients with neuroendocrine tumors." @default.
• W2935132327 created "2019-04-11" @default.
• W2935132327 creator A5002889698 @default.
• W2935132327 creator A5007325991 @default.
• W2935132327 creator A5041902578 @default.
• W2935132327 creator A5053838272 @default.
• W2935132327 creator A5069898768 @default.
• W2935132327 creator A5081675549 @default.
• W2935132327 date "2019-03-29" @default.
• W2935132327 modified "2023-10-14" @default.
• W2935132327 title "Recombinant α₁-Microglobulin Is a Potential Kidney Protector in ¹⁷⁷Lu-Octreotate Treatment of Neuroendocrine Tumors" @default.
• W2935132327 cites W1776952068 @default.
• W2935132327 cites W1924652994 @default.
• W2935132327 cites W2008740893 @default.
• W2935132327 cites W2018419826 @default.
• W2935132327 cites W2020207911 @default.
• W2935132327 cites W2030082720 @default.
• W2935132327 cites W2083764282 @default.
• W2935132327 cites W2090257199 @default.
• W2935132327 cites W2093098077 @default.
• W2935132327 cites W2111117263 @default.
• W2935132327 cites W2114802801 @default.
• W2935132327 cites W2119921005 @default.
• W2935132327 cites W2123106304 @default.
• W2935132327 cites W2125237089 @default.
• W2935132327 cites W2125398839 @default.
• W2935132327 cites W2128444145 @default.
• W2935132327 cites W2135593703 @default.
• W2935132327 cites W2148617171 @default.
• W2935132327 cites W2196736072 @default.
• W2935132327 cites W2416734619 @default.
• W2935132327 cites W2575947145 @default.
• W2935132327 cites W2809760991 @default.
• W2935132327 doi "https://doi.org/10.2967/jnumed.118.225243" @default.
• W2935132327 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6836861" @default.
• W2935132327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30926650" @default.
• W2935132327 hasPublicationYear "2019" @default.
• W2935132327 type Work @default.
• W2935132327 sameAs 2935132327 @default.
• W2935132327 citedByCount "10" @default.
• W2935132327 countsByYear W29351323272020 @default.
• W2935132327 countsByYear W29351323272021 @default.
• W2935132327 countsByYear W29351323272022 @default.
• W2935132327 countsByYear W29351323272023 @default.
• W2935132327 crossrefType "journal-article" @default.
• W2935132327 hasAuthorship W2935132327A5002889698 @default.
• W2935132327 hasAuthorship W2935132327A5007325991 @default.
• W2935132327 hasAuthorship W2935132327A5041902578 @default.
• W2935132327 hasAuthorship W2935132327A5053838272 @default.
• W2935132327 hasAuthorship W2935132327A5069898768 @default.
• W2935132327 hasAuthorship W2935132327A5081675549 @default.
• W2935132327 hasBestOaLocation W29351323271 @default.
• W2935132327 hasConcept C126322002 @default.
• W2935132327 hasConcept C150903083 @default.
• W2935132327 hasConcept C177322064 @default.
• W2935132327 hasConcept C185592680 @default.
• W2935132327 hasConcept C202751555 @default.
• W2935132327 hasConcept C207001950 @default.
• W2935132327 hasConcept C2777807558 @default.
• W2935132327 hasConcept C2779066768 @default.
• W2935132327 hasConcept C2780091579 @default.
• W2935132327 hasConcept C29730261 @default.
• W2935132327 hasConcept C2989005 @default.
• W2935132327 hasConcept C2993559085 @default.
• W2935132327 hasConcept C55493867 @default.
• W2935132327 hasConcept C71924100 @default.
• W2935132327 hasConcept C86803240 @default.
• W2935132327 hasConceptScore W2935132327C126322002 @default.
• W2935132327 hasConceptScore W2935132327C150903083 @default.
• W2935132327 hasConceptScore W2935132327C177322064 @default.
• W2935132327 hasConceptScore W2935132327C185592680 @default.
• W2935132327 hasConceptScore W2935132327C202751555 @default.
• W2935132327 hasConceptScore W2935132327C207001950 @default.
• W2935132327 hasConceptScore W2935132327C2777807558 @default.
• W2935132327 hasConceptScore W2935132327C2779066768 @default.
• W2935132327 hasConceptScore W2935132327C2780091579 @default.
• W2935132327 hasConceptScore W2935132327C29730261 @default.
• W2935132327 hasConceptScore W2935132327C2989005 @default.
• W2935132327 hasConceptScore W2935132327C2993559085 @default.
• W2935132327 hasConceptScore W2935132327C55493867 @default.
• W2935132327 hasConceptScore W2935132327C71924100 @default.
• W2935132327 hasConceptScore W2935132327C86803240 @default.
• W2935132327 hasIssue "11" @default.
• W2935132327 hasLocation W29351323271 @default.
• W2935132327 hasLocation W29351323272 @default.
• W2935132327 hasLocation W29351323273 @default.
• W2935132327 hasLocation W29351323274 @default.
• W2935132327 hasOpenAccess W2935132327 @default.
• W2935132327 hasPrimaryLocation W29351323271 @default.
• W2935132327 hasRelatedWork W1542976343 @default.
• W2935132327 hasRelatedWork W1985249499 @default.
• W2935132327 hasRelatedWork W2127304289 @default.
• W2935132327 hasRelatedWork W2153379120 @default.
• W2935132327 hasRelatedWork W2166471322 @default.
• W2935132327 hasRelatedWork W2764084485 @default.
• W2935132327 hasRelatedWork W2796636484 @default.
• W2935132327 hasRelatedWork W3040371898 @default.
• W2935132327 hasRelatedWork W3113583498 @default.

• next